Susquehanna International Group, LLP Gilead Sciences, Inc. Put Options Transaction History

Susquehanna International Group, LLP

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 15, 2024	BUY	$63.15 - $72.88 $42.6 Million - $49.1 Million	674,100 Added 47.77%	2,085,300 $143 Million
Q1 2024 May 07, 2024	BUY	$71.58 - $87.29 $21.7 Million - $26.5 Million	303,200 Added 27.36%	1,411,200 $103 Million
Q4 2023 Feb 14, 2024	SELL	$73.27 - $83.09 $8.41 Million - $9.54 Million	-114,800 Reduced 9.39%	1,108,000 $89.8 Million
Q3 2023 Nov 14, 2023	SELL	$73.94 - $80.67 $4.4 Million - $4.8 Million	-59,500 Reduced 4.64%	1,222,800 $91.6 Million
Q2 2023 Aug 11, 2023	BUY	$76.01 - $86.7 $14.1 Million - $16.1 Million	185,500 Added 16.91%	1,282,300 $98.8 Million
Q1 2023 May 16, 2023	SELL	$77.31 - $88.08 $40.2 Million - $45.8 Million	-520,500 Reduced 32.18%	1,096,800 $91 Million
Q4 2022 Feb 14, 2023	BUY	$62.32 - $89.47 $18.9 Million - $27.1 Million	303,300 Added 23.08%	1,617,300 $139 Million
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $24.6 Million - $28.1 Million	412,500 Added 45.76%	1,314,000 $81.1 Million

1,893

1.02B

12M

8.96M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $111B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.